Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.38), $0.01 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print
• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh